New Schizophrenia Drug Approved

This is a Princeton news story, published by Nature, that relates primarily to KarXT news.

Princeton news

For more Princeton news, you can click here:

more Princeton news

KarXT news

For more KarXT news, you can click here:

more KarXT news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Nature news

For more news from Nature, you can click here:

more news from Nature

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

schizophrenia therapies

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest schizophrenia treatment news, antipsychotics news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

other schizophrenia treatments

Nature

•

Revolutionary drug for schizophrenia wins US approval

Summary

Nutrition label

83% Informative

The drug, known as KarXT , targets proteins in the brain known as muscarinic receptors, which relay neurotransmitter signals between neurons and other cells.

Activating these receptors dampens the release of the chemical dopamine, a nervous-system messenger that is central to the hallmark symptoms of schizophrenia.

In clinical trials, KarXT showed signs of improving cognitive function, avoiding many of the burdensome side effects commonly associated with older antipsychotics.

Bristol Myers Squibb (BMS) in Princeton , New Jersey , acquired Karuna for approximately $14 billion this year .

Other drug makers are likewise seeing the value of targeting muscarinic receptors, pursuing various strategies to improve on the profile of KarXT .

Most industry analysts predict strong demand, with peak annual sales projected in the billions .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language